Health In Tech, Inc. (HIT) Shareholder/Analyst Call Prepared Remarks Transcript

Health In Tech, Inc. (NASDAQ:HIT) successfully conducted its Annual Meeting of Stockholders on October 3, 2025, with a significant 99.33% of outstanding common shares represented. Shareholders re-elected five directors, including CEO Tim Johnson and CFO Julia Qian, and ratified MaloneBailey as the independent auditor for fiscal year 2025. Crucially, an amendment to the 2024 Equity Incentive Plan was approved, increasing authorized Class A common stock for issuance by 3 million shares and introducing up to 2 million Class B common shares for executive officers, signaling a potential impact on dilution and executive compensation structure.

Analysis

Health In Tech, Inc. (HIT) conducted its annual stockholder meeting with an exceptionally high quorum, with 99.33% of shares entitled to vote being represented, indicating strong shareholder engagement. Shareholders approved all proposals, including the re-election of the existing board of directors—notably CEO Tim Johnson and CFO Julia Qian—which signals confidence in the current management team and ensures strategic continuity. The most material outcome was the approval of an amendment to the 2024 Equity Incentive Plan. This amendment expands the pool of Class A common stock available for issuance by 3 million shares (to 10.68 million total) and, more significantly, authorizes up to 2 million shares of Class B common stock for executive officers. This action will result in future dilution for existing shareholders and introduces a dual-class component to executive compensation, the implications of which depend on the specific rights of Class B stock. A notable discrepancy exists within the report: while 56.4 million shares were listed as outstanding on the record date, the inspector's report cited 161.6 million shares represented and entitled to vote, a material inconsistency that requires clarification as it impacts the true scale of dilution and ownership structure.

Key Decisions for Investors

• Investors should update their financial models to account for the potential dilution from the newly authorized 3 million Class A and 2 million Class B shares under the amended equity incentive plan, which will impact future earnings per share.
• It is critical to scrutinize company filings for details on the rights and conversion terms of the new Class B stock to assess whether its issuance to executives aligns with the interests of Class A common stockholders.
• Seeking clarification from Health In Tech's investor relations is advised to resolve the significant discrepancy between the number of outstanding shares (56.4M) and the number of shares entitled to vote (161.6M), as this ambiguity affects all per-share metrics.
• While the meeting's procedural nature does not necessitate immediate portfolio changes, the approved increase in equity compensation should be a key consideration in long-term valuation and governance analysis.